Review on Neuropathic Pain

  • Vishal U. Shewale Department Of Quality Assurance Techniques, KCT’S R.G.Sapkal College Of Pharmacy Anjaneri, Nashik
  • Smita S. Aher Department of Pharmaceutical Chemistry, KCT’S R.G.Sapkal College of Pharmacy Anjaneri, Nashik
  • Ravindranath B. Saudagar Department of Pharmaceutical Chemistry, KCT’S R.G.Sapkal College of Pharmacy Anjaneri, Nashik

Abstract

Neuropathic pain is defined as “Pain is observed as disease of the somatosensory nervous system.” The cause of pain is very wide-ranging and may certainly be idiopathic. Two nerve damage classifications have been described and they are outlined. These are first line and second line. Neuropathic pain is generated by electrical hyperactivity of neurons along the pain pathways. The sensory pathway consists of at least three neurons, and lesions anywhere along the pathway can lead to neuropathic pain. A successful clinical management for neuropathic pain requires balancing the advantages and side effects of available drugs, lifestyle interventions, and treating the underlying cause if possible for the management of neuropathic pain requires various lines of treatment i.e first line and second line treatment which includes various types of drugs.


Keywords: Neuropathic pain, Hyperalgesia, Neuralgia, Neuronal Hyperactivity, Neurapraxia.

Downloads

Download data is not yet available.

Author Biographies

Vishal U. Shewale, Department Of Quality Assurance Techniques, KCT’S R.G.Sapkal College Of Pharmacy Anjaneri, Nashik

Department Of Quality Assurance Techniques, KCT’S R.G.Sapkal College Of Pharmacy Anjaneri, Nashik

Smita S. Aher, Department of Pharmaceutical Chemistry, KCT’S R.G.Sapkal College of Pharmacy Anjaneri, Nashik

Department of Pharmaceutical Chemistry, KCT’S R.G.Sapkal College of Pharmacy Anjaneri, Nashik

Ravindranath B. Saudagar, Department of Pharmaceutical Chemistry, KCT’S R.G.Sapkal College of Pharmacy Anjaneri, Nashik

Department of Pharmaceutical Chemistry, KCT’S R.G.Sapkal College of Pharmacy Anjaneri, Nashik

References

1. Neuropathic pain; Vanja Basic-Kes Iris Zavoreo Marijana Bosnar-Puretic, Mira Ivankovic", Milan Bitunjac',Valbona Govori'and Vida Demarin' Acta Clin Croat 2009; 48:359-365
2. mechanisms of neuropathic pain.d.bridges,s.w.n.thompson and a.s.c rice, Bri J Anaesth 2001,87(1) 12-26.
3. drugs for nerve pain: www.painrelieffoundation.org.uk
4. drugs treatments for neuropathic pain https://www.nice.org.uk/terms-andconditions#notice-of-rights
5. guidelines for the management of neuropathic pain in primary care Final Approved APCO March 2017, NHS oxfordshire clinical commissioning group
6. Neuropathic pain-central vs peripheral injury Kathleen Meacham, Andrew Shepherd, Durga P. Mohapatra and Simon Haroutounian, Curr Pain Headache Rep (2017) 21: 28
7. lingual nerve injury,Steven b.graff-radford DDS Randolph B.evans ,MD, Headache 2003;43:975-983
8. Nerve injury and recovery, Susan E. Mackinnon, MD & Christine B. Novak, PT, MS, Washington University School of Medicine, St. Louis, Missouri, March, 2001
9. Non pharmacologic treatment of neuropathic pain using frequency specific microcurrent, AROLYN MCMAKIN, MA, DC, The Pain practitioner, Volume 20, Number 3.
10. Drugs for neuropathic pain Eija kalso,dj.aldington,RA moore, BMJ 18 Jan 2014 Vol -348
11. Multimodal approaches to the management of neuropathic pain the role of topical analgesics Oscar a.de.leon-casasola MD,Journal of pain and symptom management,Vol 33,Num 3,March 2007.
12. Pharmacological treatment Neuropathic pain review of oral and topical therapy recoomendations, Daniela amorim, . IJCNMH 2015; 2:4
13. Neuropathic pain: mechanisms of their clinical implications, steven p. cohen-jianren mao BMJ 2014;348:f7656
14 Neuropathic pain :diagnosis,pathophysiological mechanisms and treatment Ralf Barah, Andreas Binder,Gunnar Wasner, lancet neural 2010;9.page no.807-819
15 Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011; 34:2220–2224. [PubMed: 21852677]
16 Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011; 152:2836–2843. [PubMed: 22019149]
17 Finnerup NB, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016; 157:1599–1606. This is an updated grading system to guide clinical diagnosis of neuropathic pain by illustrating the significance of confirmatory tests, the role of screening tools and potential uncertainties about anatomical pain distributions. [PubMed: 27115670]
18 Dolgin E. Fluctuating baseline pain implicated in failure of clinical trials. Nat Med. 2010; 16:1053.
19 Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006; 29:1518–1522. [PubMed: 16801572]
20 Bennett MI, et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain. 2012; 153:359–365. [PubMed: 22115921]
21 Freynhagen R, et al. Screening of neuropathic pain components in patients with chronic back pain associated with nerve root compression: a prospective observational pilot study (MIPORT). Curr Med Res Opin. 2006; 22:529–537. [PubMed: 16574036]
22 Vaso A, et al. Peripheral nervous system origin of phantom limb pain. Pain. 2014; 155:1384–1391. [PubMed: 24769187]
23 Faber CG, et al. Gain of function Nav1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol. 2012; 71:26–39. [PubMed: 21698661]
24 Peyron R. Functional brain imaging: what has it brought to our understanding of neuropathic pain? A special focus on allodynic pain mechanisms. Pain. 2016; 157:S67–S71. [PubMed: 26785157]
25 Bannister K, Dickenson AH. What the brain tells the spinal cord. Pain. 2016; 157:2148–2151. [PubMed: 27023423]
26 Yarnitsky D. Role of endogenous pain modulation in chronic pain mechanisms and treatment. Pain. 2015; 156:S24–S31. [PubMed: 25789433]
27 Graven-Nielsen T, Wodehouse T, Langford RM, Arendt-Nielsen L, Kidd BL. Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. Arthritis Rheum. 2012; 64:2907–2916. [PubMed: 22421811]
28 Bennett MI, et al. Using screening tools to identify neuropathic pain. Pain. 2007; 127:199–203. [PubMed: 17182186]
29 Garcia-Larrea L. Objective pain diagnostics: clinical neurophysiology. Neurophysiol Clin. 2012; 42:187–197. [PubMed: 22632867]
30 Truini A, et al. Trigeminal small-fibre function assessed with contact heat evoked potentials in humans. Pain. 2007; 132:102–107. [PubMed: 17346887]
31 Truini A, et al. Does the epidermal nerve fibre density measured by skin biopsy in patients with peripheral neuropathies correlate with neuropathic pain? Pain. 2014; 155:828–832. This study presents the advantages and limitations of using skin biopsy and epidermal nerve fibre density measurement for the diagnosis of neuropathic pain. [PubMed: 24486884]
32 Attal N, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006; 13:1153–1169. [PubMed: 17038030]
Statistics
57 Views | 87 Downloads
How to Cite
Shewale, V. U., Aher, S. S., & Saudagar, R. B. (2019). Review on Neuropathic Pain. Journal of Drug Delivery and Therapeutics, 9(3-s), 820-824. https://doi.org/10.22270/jddt.v9i3-s.2946